Mitochondria Dysfunction and Neuroinflammation in Neurodegeneration: Who Comes First?

Alzheimer’s disease Parkinson’s disease amyotrophic lateral sclerosis inflammasome mitochondrial dysfunction neurodegeneration oxidative stress

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
16 Feb 2024
Historique:
received: 01 02 2024
revised: 13 02 2024
accepted: 14 02 2024
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: epublish

Résumé

Neurodegenerative diseases (NDs) encompass an assorted array of disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, each characterised by distinct clinical manifestations and underlying pathological mechanisms. While some cases have a genetic basis, many NDs occur sporadically. Despite their differences, these diseases commonly feature chronic neuroinflammation as a hallmark. Consensus has recently been reached on the possibility that mitochondria dysfunction and protein aggregation can mutually contribute to the activation of neuroinflammatory response and thus to the onset and progression of these disorders. In the present review, we discuss the contribution of mitochondria dysfunction and neuroinflammation to the aetiology and progression of NDs, highlighting the possibility that new potential therapeutic targets can be identified to tackle neurodegenerative processes and alleviate the progression of these pathologies.

Identifiants

pubmed: 38397838
pii: antiox13020240
doi: 10.3390/antiox13020240
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Caterina Peggion (C)

Department of Biology, University of Padova, 35131 Padova, Italy.

Tito Calì (T)

Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy.

Marisa Brini (M)

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.

Classifications MeSH